Home » Newsletters » BioWorld Science

BioWorld Science

May 22, 2008

View Archived Issues

Clinical symptom resolution following therapeutic immunization with oral HCV vaccine

Benznidazole clears parasites, induces CD8+ T-cell memory in Chagas' disease model / News in Context

GlaxoSmithKline's avian influenza virus vaccine candidate safe in children

Ribavirin effective in children with Crimean-Congo hemorrhagic fever

SIRT1 activation shows benefit in murine model of COPD

Topigen's novel multitarget antisense oligonucleotides may be useful for the treatment of asthma

Small molecule targeting microtubules and Bcl-2 effective in prostate cancer xenograft model

Advaxis files IND with FDA for phase II Lovaxin C protocol

BioMarin initiates phase I PEG-PAL study in phenylketonuria

GlobeImmune completes planned enrollment for phase II GI-5005 trial in HCV

Myogane receives orphan medicinal product designation from EMEA

Omeros initiates patient enrollment in phase I OMS-201 study

Telik initiates two phase II Telintra studies

Daiichi Sankyo acquires U3 Pharma for EUR 150 million

SIGA completes screen of small-molecule chemical library in dengue fever antiviral program

Osiris Therapeutics initiates dosing in phase II clinical trial of Prochymal in COPD

FivePrime and Pfizer enter collaboration agreement in oncology and diabetes

Merck & Co. discontinues ACHIEVE imaging study of MK-0524A in HeFH

FDA accepts Anesiva's supplemental NDA filing to expand indication for Zingo

NeoPharm initiates enrollment in phase I clinical trial of LE-DT for metastatic solid cancer

Schering-Plough will initiate two phase III studies of boceprevir in HCV genotype 1

Sunesis initiates REVEAL-1 phase II clinical trial of voreloxin in elderly patients with AML

New antiinflammatory agents disclosed in recent Merck and Kyowa Hakko patents

Novel treatments for diabetes described in recent patent literature

Recent patents report new therapeutic agents for obesity and lipoprotein disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...